The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

Our discovery has found a possible treatment that could specifically target and help patients with this disease"(Boston)—The global burden of chronic ...

Renova Health's AI and machine learning technology provides TNF with the capability to sift through several subject records.

Mineralys plans to provide additional data from the pivotal Phase 3 Launch-HTN at an upcoming medical conference and in a peer-reviewed publication. Additionally, the ongoing Transform-HTN open-label ...

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, ...

Thanks to vasodilating ingredients like L-Citrulline and Beet Root Extract, Flush Factor Plus supports better oxygen and ...

The cause of heart disease is generally clogged arteries. These blood vessels can be blocked by fatty plaque that contains ...

The drug, a copy of Jynarque, could add up to $200 million in annual revenue by FY26, strengthening Lupin’s foothold in ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters and one oral presentation on TERLIVAZ® (terlipressin) for injection in patients with ...

U.S. health officials say they'll urge foodmakers to phase out petroleum-based artificial colors in the nation’s food supply.